Bayer invests 130 million EUR in new production facility for innovative parenteral products

“It is of crucial importance that Germany and Europe pursue a clear strategy of a future-oriented innovation policy. Bayer is investing here in research and production to secure future business while strengthening the innovative power in the region,” said Stefan Oelrich, Member of the Board of Bayer AG and Head of its Pharmaceuticals Division

The project is part of a billion-dollar investment program through which Bayer AG strengthens its global pharmaceutical production network and its own innovative capabilities.

“It is great to see a German company like Bayer AG driving innovation in Berlin. This investment not only demonstrates loyalty to the location but also strengthens our city as a renowned health metropolis. It sends a clear signal from the economic and healthcare hub of Berlin. With the commissioning of the new pharmaceutical production facility, the commitment to advanced technologies and medical research is further expanded. The successful development of the healthcare industry creates more jobs and benefits our metropolitan region as a whole,” said Kai Wegner, the Governing Mayor of Berlin.

Bayer's new production facility is based on an innovative platform technology that covers a wide range of chemically and biologically based parenteral products. The highly digitized manufacturing process enables safe, fast, and sterile formulation, filling, and freeze-drying of pharmaceuticals. The highly automated robot-based filling machine combines efficient and reliable production of medications, aiming to bring them from concept to market and ultimately to the patients even faster. The facility serves critical manufacturing areas with high medical demand, such as products in the field of ophthalmology. It is intended to supply markets in the USA, Europe, and China in the future.

“The new facility is a significant milestone for our production network. It ensures that high-quality drug forms are available in sufficient quantities, that supply chains become more reliable and efficient and that patients around the world have greater security of supply,” said Holger Weintritt, Member of the Executive Committee Pharmaceuticals and Head of Product Supply at the Pharmaceuticals Division of Bayer AG. “The innovative design of the production enables maximum flexibility for the formulation and filling of aseptic products.”

The facility is located in Germany at Bayer's global pharmaceutical headquarters in Berlin, which is a key global production site for the company and is evolving into a global “Center of Excellence for Parenterals”.